These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 10494286)

  • 1. Bladder. Risk and prognostic factors--a pathologist's perspective.
    Reuter VE
    Urol Clin North Am; 1999 Aug; 26(3):481-92. PubMed ID: 10494286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Tumors of the bladder. The pathologist's point of view].
    Vieillefond A; Quillard J; Ladouch-Badré A; Meduri G; Nenert M; Matani A; Martin E
    Ann Pathol; 1989; 9(4):249-64. PubMed ID: 2675865
    [No Abstract]   [Full Text] [Related]  

  • 3. Pathologist's role in bladder cancer.
    Farrow GM
    Semin Oncol; 1979 Jun; 6(2):198-206. PubMed ID: 482961
    [No Abstract]   [Full Text] [Related]  

  • 4. Carcinoma in situ as a prognostic factor for G3pT1 bladder tumours.
    Vicente J; Laguna MP; Duarte D; Algaba F; Chéchile G
    Br J Urol; 1991 Oct; 68(4):380-2. PubMed ID: 1933158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Classification and natural history of bladder tumors].
    Allory Y
    Rev Prat; 2014 Dec; 64(10):1365-6, 1368-71. PubMed ID: 25668829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of P53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder.
    Shariat SF; Weizer AZ; Green A; Laucirica R; Frolov A; Wheeler TM; Lerner SP
    Urology; 2000 Nov; 56(5):735-40. PubMed ID: 11068290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morphologic expressions of urothelial carcinoma in situ: a detailed evaluation of its histologic patterns with emphasis on carcinoma in situ with microinvasion.
    McKenney JK; Gomez JA; Desai S; Lee MW; Amin MB
    Am J Surg Pathol; 2001 Mar; 25(3):356-62. PubMed ID: 11224606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bladder cancer redefined.
    Murphy WM
    Cancer; 1999 Nov; 86(10):1890-2. PubMed ID: 10570409
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunohistochemical assessment of basal and luminal markers in non-muscle invasive urothelial carcinoma of bladder.
    Rodriguez Pena MDC; Chaux A; Eich ML; Tregnago AC; Taheri D; Borhan W; Sharma R; Rezaei MK; Netto GJ
    Virchows Arch; 2019 Sep; 475(3):349-356. PubMed ID: 31300876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.
    Wankowicz SAM; Werner L; Orsola A; Novak J; Bowden M; Choueiri TK; de Torres I; Morote J; Freeman GJ; Signoretti S; Bellmunt J
    J Urol; 2017 Oct; 198(4):817-823. PubMed ID: 28487100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Atypical urothelial cells (AUC): A Bethesda-derived wording applicable to urinary cytopathology].
    Piaton E; Advenier AS; Benaïm G; Petrucci MD; Lechevallier FM; Ruffion A
    Ann Pathol; 2011 Feb; 31(1):11-7. PubMed ID: 21349383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of transitional cell carcinoma of the prostate in bladder cancer patients: a prospective study.
    Wood DP; Montie JE; Pontes JE; Levin HS
    J Urol; 1989 Jul; 142(1):83-5. PubMed ID: 2733111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transitional cell carcinoma in situ.
    Farrow GM; Barlebo H; Enjoji M; Chisholm G; Friedell GH; Jackse G; Kakizoe T; Koss LG; Kotake T; Vahlensieck W
    Prog Clin Biol Res; 1986; 221():85-96. PubMed ID: 3809189
    [No Abstract]   [Full Text] [Related]  

  • 14. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens.
    McKenney JK; Desai S; Cohen C; Amin MB
    Am J Surg Pathol; 2001 Aug; 25(8):1074-8. PubMed ID: 11474293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New information in the classification of urothelial tumors of the bladder].
    Guillou L
    Ann Pathol; 1999; 19(5 Suppl):S103-7. PubMed ID: 10599468
    [No Abstract]   [Full Text] [Related]  

  • 16. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression.
    Sarkis AS; Dalbagni G; Cordon-Cardo C; Zhang ZF; Sheinfeld J; Fair WR; Herr HW; Reuter VE
    J Natl Cancer Inst; 1993 Jan; 85(1):53-9. PubMed ID: 7677935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. "Normal" urothelium in patients with bladder cancer: a preliminary report from the National Bladder Cancer Collaborative Group A.
    Murphy WM; Nagy GK; Rao MK; Soloway MS; Parija GC; Cox CE; Friedell GH
    Cancer; 1979 Sep; 44(3):1050-8. PubMed ID: 476586
    [No Abstract]   [Full Text] [Related]  

  • 18. Intraepithelial lesions of the urinary bladder with a discussion of the histogenesis of urothelial neoplasia.
    Amin MB; Young RH
    Semin Diagn Pathol; 1997 May; 14(2):84-97. PubMed ID: 9179970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ki-67 index enhances the prognostic accuracy of the urothelial superficial bladder carcinoma risk group classification.
    Santos L; Amaro T; Costa C; Pereira S; Bento MJ; Lopes P; Oliveira J; Criado B; Lopes C
    Int J Cancer; 2003 Jun; 105(2):267-72. PubMed ID: 12673690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of the time period between diagnosis of muscle invasion and radical cystectomy with regard to the prognosis of transitional cell carcinoma of the urothelium in the bladder.
    May M; Nitzke T; Helke C; Vogler H; Hoschke B
    Scand J Urol Nephrol; 2004; 38(3):231-5. PubMed ID: 15204377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.